Latest Breaking News On - Imm 1 104 - Page 1 : comparemela.com

IMM-1-104 received FDA fast track designation for use in patients with pancreatic ductal adenocarcinoma who have progressed on 1 line of treatment.

United statesVincent chungBen zeskindTreatment groupDepartment of medical oncologyImmuneering corporationTherapeutics research at city of hopeTumor growth assayMedical oncologyTherapeutics researchGastrointestinal cancerPancreatic cancerImm 1 104